Pre-treatment levels of GR exon 1F promoter methylation were significantly correlated with both post-treatment PTSD symptom severity (Figure 3A) and the change in symptom severity from pre- to post-treatment (Figure 3B). The gene discussed is NR3C1; the disease is post-traumatic stress disorder.